Zebinix 200 mg tablets
Spain
Table of Contents
Package leaflet: Information for the user
Introduction
Package leaflet: information for the user
Zebinix 200 mg tablets
eslicarbazepine acetate
Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.
- Keep this leaflet, as you may need to read it again.
- If you have any questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only, and you must not give it to other people, even if they have the same symptoms as you, because it may harm them.
- If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.
Leaflet contents:
- What Zebinix is and what it is used for
- What you need to know before taking Zebinix
- How to take Zebinix
- Possible side effects
- How to store Zebinix
- Contents of the pack and other information
1. What Zebinix is and what it is used for
Zebinix contains the active substance eslicarbazepine acetate.
Zebinix belongs to a group of medicines called antiepileptics, used to treat epilepsy, a condition in which affected individuals experience repeated seizures or convulsions.
Zebinix is used:
- as a single medicine (monotherapy) in adult patients with newly diagnosed epilepsy;
- in combination with other antiepileptic medicines (adjunctive therapy) in adult, adolescent, and pediatric patients over 6 years of age who have epileptic seizures (convulsions) originating in one part of the brain (partial seizures). These seizures may or may not be followed by a seizure affecting the entire brain (secondary generalization).
Your doctor has prescribed Zebinix to reduce the number of seizures.
2. What you need to know before taking Zebinix
Do not take Zebinix:
- if you are allergic to eslicarbazepine acetate, to other carboxamide derivatives (for example, carbamazepine or oxcarbazepine, medicines used to treat epilepsy), or to any of the other ingredients of this medicine (listed in section 6);
- if you have a certain type of heart rhythm disorder (second- or third-degree atrioventricular (AV) block).
Warnings and precautions
Talk to your doctor or pharmacist before starting Zebinix.
Tell your doctor immediately:
- if you develop blisters or skin peeling and/or mucous membranes, rash, difficulty swallowing or breathing, or swelling of the lips, face, eyelids, throat, or tongue. These could be signs of an allergic reaction;
- if you experience confusion, worsening of seizures, or decreased level of consciousness, which could be signs of low blood levels of salts.
Tell your doctor:
- if you have kidney problems. Your doctor may need to adjust your dose. Zebinix is not recommended in patients with severe renal disease;
- if you have liver problems. Zebinix is not recommended in patients with severe hepatic impairment;
- if you are taking any medicine that may cause an abnormality in the ECG (electrocardiogram) known as PR interval prolongation. If you are unsure whether your current medicines may cause this effect, discuss it with your doctor;
- if you have any heart conditions such as heart failure or heart attack, or have any disturbances in heart rhythm;
- if you have seizures that begin with a generalized electrical discharge affecting both sides of the brain.
A small number of people taking antiepileptic medicines have had thoughts of self-harm or suicide. If this happens to you while taking Zebinix, contact your doctor immediately.
Zebinix may cause dizziness and/or drowsiness, especially at the beginning of treatment. Take special care while taking Zebinix to avoid accidental injuries such as falls.
Special caution with Zebinix
In post-marketing experience, serious and potentially life-threatening skin reactions have been reported in patients treated with Zebinix, including Stevens-Johnson Syndrome / toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS).
If you develop a severe rash or other skin symptoms (see section 4), stop taking Zebinix and consult your doctor or seek immediate medical attention.
In patients of Thai and Han Chinese ethnic origin, the risk of severe skin reactions associated with carbamazepine or chemically related compounds can be predicted by a blood test. Your doctor may advise you about the need for such a blood test before starting Zebinix.
Children
Zebinix must not be given to children aged 6 years or younger.
Taking Zebinix with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines. This is important because some medicines may interfere with how Zebinix works, or Zebinix may interfere with the effect of other medicines. Inform your doctor if you are taking:
- phenytoin (a medicine used to treat epilepsy), as dose adjustment may be necessary;
- carbamazepine (a medicine used to treat epilepsy), as your dose may need to be adjusted, and the following side effects of Zebinix may occur more frequently: double vision, abnormal coordination, and dizziness;
- hormonal contraceptives (such as the contraceptive pill), as Zebinix may reduce their effectiveness;
- simvastatin (a medicine used to lower cholesterol levels), as your dose may need to be adjusted;
- rosuvastatin, a medicine used to lower cholesterol levels;
- the anticoagulant warfarin;
- monoamine oxidase inhibitor (MAOI) antidepressants;
- do not take oxcarbazepine (a medicine used to treat epilepsy) together with Zebinix, as it is unknown whether it is safe to take these two medicines together.
See the section “Pregnancy and breastfeeding” for recommendations on contraception.
Pregnancy and breastfeeding
The use of Zebinix is not recommended during pregnancy, as the effects of Zebinix on pregnancy and the unborn child are unknown.
If you are planning to become pregnant, speak with your doctor before stopping contraception and before becoming pregnant. Your doctor may decide to change your treatment.
There is limited data on the use of eslicarbazepine acetate in pregnant women.
Studies have shown an increased risk of congenital malformations and neurological development problems (brain development) in children of women taking antiepileptic medicines, particularly when more than one antiepileptic medicine is taken at the same time.
If you are or think you may be pregnant, inform your doctor immediately. You must not stop taking your medicine until you have discussed it with your doctor. Stopping your medication without consulting your doctor may cause seizures, which could be dangerous for you and your unborn child. Your doctor may decide to change your treatment.
If you are a woman of childbearing potential and not planning to become pregnant, you must use an effective method of contraception during treatment with Zebinix. Zebinix may affect the effectiveness of hormonal contraceptives such as the contraceptive pill, making them less effective in preventing pregnancy. Therefore, you are advised to use other safe and effective forms of contraception while taking Zebinix. Talk to your doctor, who will discuss with you the most appropriate type of contraception to use while taking Zebinix. If Zebinix treatment is discontinued, you should continue using an effective method of contraception until the end of the current menstrual cycle. If you take Zebinix during pregnancy, your baby may also be at risk of bleeding problems immediately after birth. Your doctor may give you and your baby a medicine to prevent this.
Do not breast-feed while taking Zebinix. It is unknown whether Zebinix passes into breast milk.
Driving and using machines
Zebinix may cause dizziness, drowsiness, and affect your vision, particularly at the beginning of treatment. If this occurs, do not drive and do not use any tools or machines.
3. How to take Zebinix
Follow exactly the instructions for use of this medicine given by your doctor. If in doubt, consult your doctor or pharmacist again.
Adults
Starting dose
400 mg once daily for one or two weeks before increasing to the maintenance dose. Your doctor will decide whether you should take this dose for one or two weeks.
Maintenance dose
The usual maintenance dose is 800 mg once daily.
Depending on how you respond to Zebinix, the dose may be increased to 1,200 mg once daily. If you are taking Zebinix alone (monotherapy), your doctor may consider increasing your dose to 1,600 mg once daily.
Patients with renal problems
If you have kidney problems, you will generally be given a lower dose of Zebinix. Your doctor will determine the correct dose for you. Zebinix is not recommended if you have severe kidney problems.
Elderly patients (over 65 years of age)
If you are an elderly patient and are taking Zebinix as monotherapy, the 1,600 mg dose is not suitable for you.
Children over 6 years of age
Starting dose
The initial dose is 10 mg per kg of body weight once daily for one or two weeks, before increasing to the maintenance dose.
Maintenance dose
Depending on the response to Zebinix, the dose may be increased by 10 mg per kg of body weight at intervals of one or two weeks, up to a maximum of 30 mg per kg of body weight. The maximum dose is 1,200 mg once daily.
Children ≥ 60 kg
Children with a body weight of 60 kg or more should take the same dose as adults.
The oral suspension, another pharmaceutical form of the medicine, may be more suitable for administration in children. Please consult your doctor or pharmacist.
Method and route of administration
Zebinix is administered orally. Swallow the tablet with a glass of water.
Zebinix may be taken with or without food.
If you have difficulty swallowing the whole tablet, you may crush it and mix it with a small amount of water or apple puree and take it immediately.
The tablet may be divided into equal doses.
If you take more Zebinix than you should
If you accidentally take more Zebinix than you should, you may be at risk of having more seizures, or you may feel that your heartbeat is irregular or faster. Contact your doctor or go immediately to a hospital if you experience any of these symptoms. Take the medicine packaging with you so that the doctor knows what you have taken.
If you forget to take Zebinix
If you forget to take a dose, take it as soon as you remember and then continue as usual. Do not take a double dose to make up for a missed dose.
If you stop taking Zebinix
Do not suddenly stop taking the tablets. If you do, you may be at risk of having more seizures. Your doctor will decide how long you should take Zebinix. If your doctor decides to discontinue Zebinix treatment, your dose will usually be gradually reduced. It is important that you complete the treatment as instructed by your doctor; otherwise, your symptoms may worsen.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
4. Possible adverse effects
Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.
The following adverse effects may be very serious. If they occur, stop taking Zebinix immediately and contact a doctor or go to a hospital straight away, as you may require urgent medical treatment:
- blistering or peeling of the skin and/or mucous membranes, rash, difficulty swallowing or breathing, swelling of the lips, face, eyelids, throat or tongue. These could be signs of an allergic reaction.
Very common adverse effects (may affect more than 1 in 10 people) are:
- dizziness or drowsiness.
Common adverse effects (may affect up to 1 in 10 people) are:
- feeling unsteady, or of spinning or floating;
- nausea or vomiting;
- headache;
- diarrhoea;
- double or blurred vision;
- difficulty concentrating;
- feeling tired or lack of energy;
- tremor;
- skin rash;
- blood tests showing low sodium levels;
- decreased appetite;
- difficulty sleeping;
- difficulty with movement coordination (ataxia);
- weight gain.
Uncommon adverse effects (may affect up to 1 in 100 people) are:
- clumsiness of movements;
- allergy;
- constipation;
- seizures;
- underactive thyroid gland. Symptoms include decreased levels of thyroid hormones (detected in blood tests), intolerance to cold, enlargement of the tongue, brittle and thin nails or hair, and low body temperature;
- liver problems (such as increased liver enzymes);
- high blood pressure or a marked increase in blood pressure;
- low blood pressure, or decreased blood pressure upon standing;
- blood tests showing low levels of salts (including chloride), or a reduction in the number of red blood cells;
- dehydration;
- changes in eye movements, blurred vision or red eyes;
- falls;
- thermal burns;
- poor memory or forgetfulness;
- crying, feeling depressed, nervousness or confusion, lack of interest or emotions;
- inability to speak, write or understand spoken or written language;
- agitation;
- attention deficit/hyperactivity;
- irritability;
- mood changes or hallucinations;
- difficulty speaking;
- nosebleeds;
- chest pain;
- tingling or numbness sensation anywhere in the body;
- migraine;
- burning sensation;
- abnormal sensation to touch;
- changes in sense of smell;
- ringing in the ears;
- difficulty hearing;
- swelling of arms and legs;
- heartburn, stomach discomfort, abdominal pain, bloating and abdominal discomfort or dry mouth;
- black stools;
- gum inflammation or toothache;
- sweating or dry skin;
- itching;
- skin changes (e.g. skin redness);
- hair loss;
- urinary tract infection;
- general malaise, weakness or chills;
- weight loss;
- muscle pain, limb pain, muscle weakness;
- bone metabolism disorder;
- increased bone proteins;
- flushing, cold extremities;
- slower or irregular heartbeat;
- extreme drowsiness;
- sedation;
- motor neurological disorder where muscles contract, causing twisting movements, repetitive movements or abnormal postures. Symptoms include tremors, pain and cramps;
- drug toxicity;
- anxiety.
Adverse effects with unknown frequency (cannot be estimated from available data) are:
- Reduction in platelets, increasing the risk of bleeding or bruising;
- Severe back or stomach pain (caused by inflammation of the pancreas);
- Reduction in white blood cells, making infections more likely;
- Red spots or circular lesions, often with central blisters on the trunk, skin peeling, mouth ulcers, throat, nose, genitals and eyes, red and inflamed eyes, which may be preceded by fever and/or flu-like symptoms (Stevens-Johnson syndrome / toxic epidermal necrolysis);
- Initially flu-like symptoms, facial rash, generalized rash, high body temperature, elevated liver enzymes, blood abnormalities (eosinophilia), enlarged lymph nodes and other systemic symptoms (drug reaction with eosinophilia and systemic symptoms, also known as DRESS or drug hypersensitivity syndrome);
- Severe allergic reaction causing swelling of the face, throat, hands, feet, ankles or lower legs;
- Hives (itchy skin rash);
- Lethargy, confusion, muscle spasms or a marked worsening of seizures (possible symptoms of low blood sodium levels due to inappropriate antidiuretic hormone (ADH) secretion).
Use of Zebinix is associated with an ECG (electrocardiogram) abnormality called PR interval prolongation. Adverse effects related to this ECG abnormality may occur (e.g. fainting and slowing of the heartbeat).
Bone disorders including osteopenia and osteoporosis (thinning of the bones) and fractures have been reported with structurally related antiepileptic medicines such as carbamazepine and oxcarbazepine. Speak with your doctor or pharmacist if you are on long-term antiepileptic treatment, have a history of osteoporosis, or are taking steroids.
Reporting of adverse effects
If you experience any adverse effect, talk to your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You may also report them directly through the national reporting system detailed in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.
5. Storage of Zebinix
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister, the bottle, and the outer carton after the letters EXP. The expiry date refers to the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of via wastewater drains or household waste. Ask your pharmacist how to dispose of any unused medicine and its packaging. This will help protect the environment.
6. Contents of the pack and other information
Composition of Zebinix
- The active substance is eslicarbazepine acetate. Each tablet contains 200 mg of eslicarbazepine acetate.
- The other components are povidone K29/32, sodium croscarmellose, and magnesium stearate.
Appearance of the product and contents of the pack
Zebinix 200 mg tablets are white, oblong-shaped tablets, 11 mm in length. The tablets are marked with the imprint “ESL 200” on one side and are scored on the opposite side. The tablet can be divided into equal doses.
The tablets are packed in blisters, in cardboard boxes containing 20 or 60 tablets, or in HDPE bottles with child-resistant closures, in cardboard boxes containing 60 tablets.
Only certain pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
BIAL - Portela & Cª, S.A., Av. da Siderurgia Nacional,
4745-457 S. Mamede do Coronado
Portugal
Telephone: +351 22 986 61 00
Fax: +351 22 986 61 99
Email: [email protected]
Further information on this medicinal product is available by contacting the local representative of the Marketing Authorization Holder:
Belgium/Belgium/Belgium BIAL-Portela & Cª., S.A. Tel/Tel: + 351 22 986 61 0 (Portugal) | Luxembourg/Luxembourg BIAL-Portela & Cª., S.A. Tel/Tel: + 351 22 986 61 00 (Portugal) |
???????? BIAL-Portela & Cª., S.A. Tel: + 351 22 986 61 00 (??????????) | Hungary BIAL-Portela & Cª., S.A. Tel.: + 351 22 986 61 0 (Portugal) |
Czech Republic BIAL-Portela & Cª., S.A. Tel: + 351 22 986 61 00 (Portugal) | Malta BIAL-Portela & Cª., S.A. Tel: + 351 22 986 61 00 (Malta) |
Denmark Nordicinfu Care AB Tlf: +45 (0) 70 28 10 24 | Netherlands BIAL-Portela & Cª., S.A. Tel/Tel: + 351 22 986 61 00 (Portugal) |
Germany BIAL-Portela & Cª., S.A. Tel: + 351 22 986 61 00 (Portugal) | Norway Nordicinfu Care AB Tlf: +47 (0) 22 20 60 00 |
Estonia BIAL-Portela & Cª, S.A. Tel: +351 22 986 61 00 (Portugal) | Austria BIAL-Portela & Cª., S.A. Tel: + 351 22 986 61 00 (Portugal) |
Greece ARRIANI FARMACEUTIKI S.A. Tel: + 30 210 668 3000 | Poland BIAL-Portela & Cª, S.A. Tel.: + 351 22 986 61 00 (Poland) |
Spain Laboratorios BIAL, S.A. Tel: + 34 91 562 41 96 | Portugal BIAL-Portela & Cª., S.A. Tel.: + 351 22 986 61 00 |
France BIAL-Portela & Cª., S.A. Tel: + 351 22 986 61 00 (Portugal) | Romania BIAL-Portela & Cª, S.A. Tel: + 351 22 986 61 00 (Romania) |
Croatia BIAL-Portela & Cª, S.A. Tel: + 351 22 986 61 00 (Portugal) | Slovenia BIAL-Portela & Cª, S.A. Tel: + 351 22 986 61 00 (Slovenia) |
Ireland BIAL-Portela & Cª., S.A. Tel: + 351 22 986 61 00 (Portugal) | Slovak Republic BIAL-Portela & Cª., S.A. Tel: + 351 22 986 61 00 (Slovakia) |
Iceland Nordicinfu Care AB Sími: +46 (0) 8 601 24 40 | Finland Nordicinfu Care AB Puh/Tel: +358 (0) 207 348 760 |
Italy BIAL-Portela & Cª., S.A. Tel: + 351 22 986 61 00 (Italy) | Sweden Nordicinfu Care AB Tel: +46 (0) 8 601 24 40 |
Cyprus BIAL-Portela & Cª, S.A. Tel: + 351 22 986 61 00 (Cyprus) | United Kingdom BIAL-Portela & Cª., S.A. Tel: + 351 22 986 61 00 (Portugal) |
Latvia BIAL-Portela & Cª, S.A. Tel: + 351 22 986 61 00 (Latvia) | |
Lithuania BIAL-Portela & Cª, S.A. Tel: + 351 22 986 61 00 (Lithuania) |
Date of the most recent review of this leaflet: <{MM YYYY}>
Detailed information on this medicine is available on the website of the European Medicines Agency http://www.ema.europa.eu.